Large group onboarding of Omnipod 5 automated insulin delivery system-Experience from a UK secondary care diabetes service
- PMID: 39887776
- PMCID: PMC11929554
- DOI: 10.1111/dme.70000
Large group onboarding of Omnipod 5 automated insulin delivery system-Experience from a UK secondary care diabetes service
Conflict of interest statement
H Thabit reports having received speaker honoraria from Eli Lilly and Dexcom Inc., having served on advisory panels for Medtronic, Sanofi and Roche and having received research support from Dexcom Inc. AC, S McGriskin, L Findlow, A Urwin, S Ohol, S Thomas, R Obsiye and J Schofield report no relevant conflict of interest.
References
-
- National Institute for Health and Care Excellence (NICE) . Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes: technology appraisal guidance TA 943. Accessed November 28 2024 https://www.nice.org.uk/guidance/ta943 2023.
-
- Renard E, Weinstock RS, Aleppo G, et al. Efficacy and safety of a tubeless AID system compared with pump therapy with CGM in the treatment of type 1 diabetes in adults with suboptimal Glycemia: a randomized, parallel‐group clinical trial. Diabetes Care. 2024;47(12):2248‐2257. doi:10.2337/dc24-1550 - DOI - PMC - PubMed
Publication types
LinkOut - more resources
Full Text Sources
